# A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

> **NCT06105255** · PHASE1 · COMPLETED · sponsor: **InventisBio Co., Ltd** · enrollment: 45 (actual)

## Conditions studied

- Healthy Male

## Interventions

- **DRUG:** D-1553

## Key facts

- **NCT ID:** NCT06105255
- **Lead sponsor:** InventisBio Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-24
- **Primary completion:** 2024-02-02
- **Final completion:** 2024-02-02
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06105255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06105255, "A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06105255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*